Dr Mathias Rummel talks to ecancer about bendamustine and the changes in standard treatment for lymphoma at the ASCO 2012 Annual Meeting in Chicago, June 2012.

Dr Rummel challenged the current standard, CHOP rituximab, because of its high toxicity and, in some cases, inability to provide a cure.

The treatment used in this clinical trial was combination chemotherapy with bendamustine and rituximab. Progression-free survival was double to nearly six years, compared to the previous standard treatment.

Audio only